1+ day, 2+ hour ago   (401+ words) The Clinical Trial Vanguard Tam-Peli meets primary endpoint for relapsed small-cell lung cancer in phase III trial Topotecan has been the default second-line chemotherapy for relapsed small-cell lung cancer for decades, and its survival benefit in that setting is modest…...

1+ day, 2+ hour ago   (171+ words) clinicaltrialvanguard.com CMO Location Drives Site Selection for Parkinsonian Imaging Trial When a radiopharmaceutical expires within hours of manufacture, the drug’s chemistry, not the disease’s prevalence, decides where a trial can run. That constraint shaped every decision in a site…...

4+ day, 2+ hour ago   (422+ words) The Clinical Trial Vanguard Insilico Medicine Begins Phase III Trial of AI-Discovered Drug Rentosertib for IPF Rentosertib just cleared a threshold no AI-discovered drug has reached before: 320 patients, 47 sites, 52 weeks of treatment in a randomized, double-blind, placebo-controlled Phase III. Insilico Medicine…...

5+ day, 2+ hour ago   (336+ words) The Clinical Trial Vanguard Novartis Pays $50M Milestone as MRT-6160 Enters Phase 2 for Sjögren’s Disease A $50 million check is the clearest signal yet that Novartis believes VAV1 degradation works in humans. Monte Rosa Therapeutics triggered that milestone payment on September 8, 2026, when Novartis…...

5+ day, 2+ hour ago   (322+ words) The Clinical Trial Vanguard BridgeBio Shifts BBO-8520 Focus to KRAS Combinations in Second-Line NSCLC A 63% objective response rate from a Phase 1 monotherapy arm is an unusual number to anchor a strategic pivot on, but that is what BridgeBio Oncology Therapeutics…...

5+ day, 1+ hour ago   (790+ words) The Clinical Trial Vanguard A 25% Sample Size Cut Sounds Like a Win, Until You See the Amendment Queue A clinical operations lead gets the news from her biostatistics team: the new digitally enhanced composite endpoint just cut the required sample…...

1+ week, 2+ hour ago   (334+ words) The Clinical Trial Vanguard Tekton Research Sites Enroll 60 Participants in Phase 2 Obesity Trial, Triple Goal Enrolling three times the planned number of participants is rare enough that it usually points to something structural, not just enthusiasm. Tekton Research’s San Antonio…...

1+ week, 1+ day ago   (383+ words) The Clinical Trial Vanguard FDA Guidance Expands Cancer Trial Eligibility, Reshaping Feasibility Models Forty percent of Phase III cancer trials explicitly barred patients with an ECOG performance status of 2 or higher, and among trials that allowed those patients, they made…...

1+ week, 4+ day ago   (527+ words) The Clinical Trial Vanguard Ultragenyx’s apazunersen fails Phase 3 primary endpoint in Angelman syndrome Two years of Phase 1/2 momentum collapsed in a single readout: Ultragenyx’s Phase 3 Aspire study for apazunersen (GTX-102) in Angelman syndrome failed both its primary endpoint and its…...

1+ week, 4+ day ago   (198+ words) That failure carries weight far beyond the TNBC space. Every immuno-oncology sponsor running a Phase 3 program with a PD-L1 inhibitor, in any indication, should be reading the B-59 readout and asking a harder question than “did it work?” The harder question…...